IP Library Patent Application 12963520
Patent Application
App. No. 12/963,520

GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR EXTENDED RELEASE OF POLYPEPTIDES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/963,520
Abstract

Gastric retentive dosage forms for controlled release of polypeptides are described. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

Claims (20)

1 . An oral gastric retentive dosage form comprising,

a polymeric matrix wherein the polymeric matrix is comprised of at least one hydrophilic polymer, wherein upon imbibition of fluid the polymeric matrix swells to a size sufficient for gastric retention in a stomach in a fed mode, and

a polypeptide component dispersed in the polymeric matrix.

2 . The dosage form of claim 1 , wherein the polypeptide component comprises a plurality of micropellets.

3 . The dosage form of claim 1 , comprising about 5 wt % to about 95 wt % of the polypeptide component.

4 . The dosage form of claim 2 , wherein each of the plurality of micropellets comprises one or more polypeptides.

5 . The dosage form of claim 4 , wherein at least one of the one or more polypeptides is an enzyme.

6 . The dosage form of claim 5 , wherein the enzyme is a pancreatic enzyme.

7 . The dosage form of claim 2 , wherein each of the plurality of micropellets comprises an enteric coating.

8 . The dosage form of claim 7 , wherein the enteric coating comprises an inner and an outer layer.

9 . The dosage form of claim 6 , wherein the enzyme maintains at least about 30% of its activity after exposure of the micropellet to gastrointestinal fluid.

10 . The dosage form of claim 1 , wherein about 20%-50% of the polypeptide component is released from the dosage form within about 1 hour after immersion in a gastric fluid.

11 . The dosage form of claim 1 , wherein at least about 80% of the polypeptide component is released from the dosage form within about 8 hours after immersion in a gastric fluid.

12 . A method of treating a disease which results in a polypeptide deficiency comprising,

administering to a subject in a fed mode an oral gastric retentive dosage form comprising,

a polymeric matrix wherein the polymeric matrix is comprised of at least one hydrophilic polymer, wherein upon imbibition of fluid the polymeric matrix swells to a size sufficient for gastric retention in a stomach in the fed mode, and

a polypeptide component dispersed in the polymeric matrix.

13 . The method according to claim 12 , wherein the polypeptide component comprises a plurality of micropellets.

14 . The method according to claim 12 , wherein the polypeptide component comprises an enzyme.

15 . The method according to claim 14 , wherein the enzyme is a pancreatic enzyme.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Feb 13, 2020
From: DEERFIELD PRIVATE DESIGN FUND III, L.P., AS COLLATERAL AGENT
To: ASSERTIO THERAPEUTICS, INC. (F/K/A DEPOMED, INC.)
Reel/Frame 051930/0778 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBERS 09402976, 10196590, 11562002,11562173,12047388,13078575,13541314,13541325, 14747289 PREVIOUSLY RECORDED ON REEL 047322 FRAME 0843. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded May 7, 2019
From: DEPOMED, INC.
To: ASSERTIO THERAPEUTICS, INC.
Reel/Frame 049110/0550 →
MERGER Recorded Sep 11, 2018
From: DEPOMED, INC.
To: ASSERTIO THERAPEUTICS, INC.
Reel/Frame 047322/0843 →
SECURITY INTEREST Recorded Apr 2, 2015
From: DEPOMED, INC.
To: DEERFIELD PRIVATE DESIGN FUND III, L.P.
Reel/Frame 035355/0039 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2011
From: MILLER, JENNIFER L.; FELL, RYAN DOUGLAS; COWLES, VERNE EARLE
To: DEPOMED, INC.
Reel/Frame 025733/0618 →